Cantor Fitzgerald Forecasts MDGL FY2026 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the biopharmaceutical company will post earnings of ($2.78) per share for the year. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share.

Several other equities research analysts also recently weighed in on MDGL. UBS Group increased their price target on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. B. Riley reiterated a "buy" rating and set a $460.00 price target (up from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. HC Wainwright upped their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Citigroup boosted their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and set a $443.00 price target on shares of Madrigal Pharmaceuticals in a report on Thursday, April 24th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $420.63.

Madrigal Pharmaceuticals Stock Performance

MDGL traded down $1.64 during trading on Tuesday, reaching $295.57. 270,711 shares of the company's stock were exchanged, compared to its average volume of 361,827. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The company's fifty day simple moving average is $297.45 and its 200-day simple moving average is $314.69. Madrigal Pharmaceuticals has a 1 year low of $200.63 and a 1 year high of $377.46. The stock has a market capitalization of $6.56 billion, a P/E ratio of -11.79 and a beta of -1.08.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.62) by $0.30. The business had revenue of $137.25 million for the quarter, compared to analyst estimates of $112.79 million. During the same period in the previous year, the company posted ($7.38) earnings per share.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC grew its position in shares of Madrigal Pharmaceuticals by 0.3% in the first quarter. Mutual of America Capital Management LLC now owns 11,263 shares of the biopharmaceutical company's stock valued at $3,731,000 after purchasing an additional 31 shares during the period. Pitcairn Co. increased its stake in Madrigal Pharmaceuticals by 3.2% during the 4th quarter. Pitcairn Co. now owns 1,060 shares of the biopharmaceutical company's stock worth $327,000 after buying an additional 33 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 38.9% during the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock valued at $52,000 after acquiring an additional 44 shares during the last quarter. Sanctuary Advisors LLC lifted its position in shares of Madrigal Pharmaceuticals by 5.2% in the fourth quarter. Sanctuary Advisors LLC now owns 1,247 shares of the biopharmaceutical company's stock valued at $422,000 after acquiring an additional 62 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Madrigal Pharmaceuticals by 131.4% during the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.